Breaking News, Collaborations & Alliances

Hovione Signs Exclusive License Agreement with JIXING

JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.

Author Image

By: Charlie Sternberg

Associate Editor

Ji Xing Pharmaceuticals Limited. has entered an exclusive license agreement for a preclinical ophthalmology program, JX08, with Hovione, a leader in spray drying and particle engineering.   JIXING is a biotechnology company headquartered in Shanghai and backed by RTW Investments, LP (RTW), a life sciences investment firm, that is focused on advancing innovative medicines for patients with ophthalmic and cardiovascular diseases. Under the license agreement, JIXING will receive global rights to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters